-
1.发明公开TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE 审中-公开物质与LIPIDTRANSPORT- WECH SELGE相关疾病的反义自然科学成绩单针对LIPIDTRANSPORT-和物质WECH SELGEN阻垢处理
公开(公告)号：EP2427553A4
公开(公告)日：2012-11-07
申请号：EP10772845
申请日：2010-05-06
申请人： OPKO CURNA LLC
IPC分类号： C12N15/113 , A61K31/713 , A61K48/00 , C12N15/63
CPC分类号： C12N15/113 , A61K31/713 , A61K48/00 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12Y203/01043
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Lipid transport and metabolism gene, in particular, by targeting natural antisense polynucleotides of a Lipid transport and metabolism gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of a Lipid transport and metabolism genes.
摘要翻译： 本发明涉及反义寡核苷酸没有调节和/或脂质转运和代谢的基因，特别是功能的表达，通过靶向脂质转运和代谢的基因的天然反义多核苷酸。 因此，本发明涉及反义寡核苷酸合成的识别和它们在治疗与脂质转运和代谢的基因的表达相关的疾病和病症的用途。
-
2.发明公开TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE 有权治疗胶原基因相关BY抑制天然反义转录到一个胶原基因疾病的
公开(公告)号：EP2443237A2
公开(公告)日：2012-04-25
申请号：EP10790092.0
申请日：2010-06-16
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N15/12 , A61K31/713 , A61K48/00
CPC分类号： C12N15/113 , A61K31/713 , A61L27/3633 , C07K14/78 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12N2310/315
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes.
摘要翻译： 本发明涉及反义寡核苷酸没有调节和/或胶原蛋白基因的功能的表达，特别是，通过靶向胶原基因的天然反义多核苷酸。 因此，本发明涉及反义寡核苷酸合成的识别和它们在治疗与胶原的基因的表达相关的疾病和病症的用途。
-
3.发明公开TREATMENT OF ANTIVIRAL GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN ANTIVIRAL GENE 有权病毒基因反相关疾病的反义自然科学成绩单对反病毒基因阻垢处理
公开(公告)号：EP2435571A2
公开(公告)日：2012-04-04
申请号：EP10781271.1
申请日：2010-05-28
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N15/82
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2310/14 , C12N2310/315 , Y02A50/463
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Antiviral gene, in particular, by targeting natural antisense polynucleotides of an Antiviral gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Antiviral genes.
-
4.发明公开TREATMENT OF TRISTETRAPROLINE (TTP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TTP 有权TRISTETRAPROLIN予以治疗（TTP）-BEDINGTEN病从抑制天然反义转录反对的TTP
公开(公告)号：EP2427552A2
公开(公告)日：2012-03-14
申请号：EP10772814.9
申请日：2010-05-06
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N15/63 , A61K31/713
CPC分类号： C12N15/113 , A61K31/713 , C12N2310/11 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12Q1/6876 , Y10T436/143333
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tristetraproline (TTP), in particular, by targeting natural antisense polynucleotides of Tristetraproline (TTP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TTP.
-
5.发明公开TREATMENT OF 'C TERMINUS OF HSP70-INTERACTING PROTEIN' (CHIP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO CHIP 审中-公开芯片的处理（HSP70相互作用蛋白的C-末端）-BEDINGTEN疾病阻抑的天然反义转录物AGAINST芯片的
公开(公告)号：EP2467482A2
公开(公告)日：2012-06-27
申请号：EP10810639.4
申请日：2010-08-20
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , A61K48/00 , A61K31/7088 , A61P25/00 , A61P37/00
CPC分类号： C12Q1/6823 , A61K31/7088 , C12N15/113 , C12N2310/11 , C12N2310/315 , C12Q2600/136
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'C terminus of HSP70-Interacting Protein' (CHIP), in particular, by targeting natural antisense polynucleotides of 'C terminus of HSP70-Interacting Protein' (CHIP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of CHIP.
摘要翻译： 本发明涉及，（特别地，通过靶向的CHIP'HSP70-相互作用蛋白的C末端的自然反义多核苷酸的反义寡核苷酸没有调制的“HSP70相互作用蛋白的C末端”（CHIP）的表达和/或功能 ）。 因此，本发明涉及反义寡核苷酸合成的识别和它们在治疗与CHIP的表达相关的疾病和病症的用途。
-
6.发明公开TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TNFR2 有权治疗肿瘤坏死因子受体2（TNFR2）ASSOCIATED阻抑的天然反义转录物AGAINST TNFR2疾病的
公开(公告)号：EP2446036A2
公开(公告)日：2012-05-02
申请号：EP10792665.1
申请日：2010-06-24
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N15/63 , C12N15/12 , C07K14/715 , A61K48/00
CPC分类号： C12N15/1138 , A61K31/711 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2320/30
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.
-
7.发明公开TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 审中-公开治疗转录因子E3（TFE3）相关的疾病及胰岛素受体底物2（IRS 2）抑制天然反义转录反对TFE3的
公开(公告)号：EP2432882A2
公开(公告)日：2012-03-28
申请号：EP10778499.3
申请日：2010-05-21
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , C12N15/63 , A61K31/713 , A61K48/00 , C12Q1/68
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TFE3 and/or IRS2.
-
8.发明公开TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO VEGF 有权治疗血管内皮生长因子（VEGF）ASSOCIATED阻抑的天然反义转录物抗VEGF疾病的
公开(公告)号：EP2370581A2
公开(公告)日：2011-10-05
申请号：EP09831074.1
申请日：2009-12-02
申请人： Opko Curna, LLC
CPC分类号： C12N15/1136 , A61K31/7088 , A61K31/712 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12N2310/315 , C12Q1/6816 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/156
摘要： Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.
-
9.发明公开TREATMENT OF 'IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN' (IQGAP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IQGAP 审中-公开IQGAP（“IQ MOTIF含酶激活蛋白”）的治疗 - 相关疾病BY抑制天然反义转录反对IQGAP的
公开(公告)号：EP2470657A2
公开(公告)日：2012-07-04
申请号：EP10815846.0
申请日：2010-08-25
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , A61K48/00 , A61K31/7088 , C12N15/63 , C12N15/52
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/111 , C12N2310/113 , C12N2310/3125 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/316 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/323 , C12N2310/3231
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of 'IQ motif containing GTPase activating protein' (IQGAP), in particular, by targeting natural antisense polynucleotides of 'IQ motif containing GTPase activating protein' (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.
-
10.发明公开TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT) 审中-公开沉默调节治疗（SIRT）-BEDINGTEN病从天然反义转录针对抗衰老酶抑制（SIRT）
公开(公告)号：EP2467481A2
公开(公告)日：2012-06-27
申请号：EP10802960.4
申请日：2010-07-23
申请人： Opko Curna, LLC
IPC分类号： C12N15/113 , A61K31/713 , A61K48/00
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/315 , C12Y305/01098
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.02 秒)
